Low-Grade Glioma
Low-Grade Gliomas are slow-growing primary brain tumors defined by IDH mutation and 1p/19q status. Molecular features refine prognosis and treatment strategies.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Low-Grade Glioma in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| BRAF |
|
Defined at the solid tumor level and applicable to Low-Grade Glioma and other solid tumor cancers.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Low-Grade Glioma. Select a therapy to view the specific approval and eligible tests.
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High)
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High); TMB (TMB ≥ 10 mutations per megabase)
BRAF (V600 and BRAF fusions)
RET (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)